A discerning use of the clinical laboratory for the diagnosis and management of gastrointestinal diseases is highly desirable and involves, at the least, a well-rounded knowledge of the literature and a healthy skepticism and mature judgment. A case in point is the utilization of the assay for carcinoembryonic antigen (CEA) employed with increasing 
A discerning use of the clinical laboratory for the diagnosis and management of gastrointestinal diseases is highly desirable and involves, at the least, a well-rounded knowledge of the literature and a healthy skepticism and mature judgment. A case in point is the utilization of the assay for carcinoembryonic antigen (CEA) employed with increasing frequency in our hospital since 1976.* Under study protocol conditions, CEA is reported by some investigators to be a reliable monitor of disease recurrence after primary tumor resection (1-3)as well as a prognosticator, when used preoperatively, to identify those patients at risk for developing recuri~ent disease (4, 5) . Under nonprotocol conditions, however, it was not clear whether the CEA' test, as it is currently being employed by physicians, was having an appreciable impact upon patient managemen t and outcome at our medical center. In addition, there was little data on the accuracy with which gastroenterologists and other physicians know the sensitivity/specificity or the cost of this test. The latter is important because, while the expense of a single serum assay would seem minor compared to that of many other diagnostic modalities, it has been proposed that aggregate physician use of small laboratory tests and procedures has a far greater impact upon health care costs than the new expensive technologies in the class of the computerized tomography scanner (6) .
The purpose of this study was to explore three aspects of the use of the CEA test in a medical center setting where the opportunity for physicians to keep up to date in the proper utilization of the clinical laboratory should be optimal. These were: (I) physician knowledge of the proper indications, interpretation, and cost of the test; (2) MATERIALS AND METHODS General. The starting point of our study was the serum CEA determinations (total of 1188, exception noted below) ordered on inpatients and outpatients at Duke University Medical Center in the year 1979. All of these tests were performed in a central facility (Nuclear Medicine Department) using a commercially available reagent kit (Roche CEAtm): Only CEA tests drawn in a breast oncology clinic were excluded from study because (1) CEA determinations were automatically drawn on every patient under protocol and hence did not reflect individual physician practice patterns in caring for patients, and (2) the CEA test employed was an experimental procedure under evaluation and differed from the standard CEA technique used in the rest of the medical center.
Physician Perception of CEA Indications and Value. The identity of the ordering physician for CEA assays performed during one month (sample 1, see below) was determined by inspection of the medical record, and a questionnaire was mailed to each within three weeks of his/her order. Physicians were asked to denote their indications for use of the CEA assay and their perceptions of false positives, false negatives, and cost (see Appendix). Responses were Obtained from every physician polled (45) who ordered a CEA that month. Instances in which ddctors had no opinion or gave an inappropriate (uninterpretable) answer were tabulated separately and are shown in the results.
Pattern of Usage of CEA Test. Because of the large number of CEA test results involved, sampling techniques were employed. Two separate subsets (Figure 1 ), conveniently composed of approximately 10% of all 1979 CEA determinations, were chosen to permit an assessment of consistency of findings from sample to sample, and data were collected in a predetermined manner (see below). Sample 1 was composed of the 111 instances in which a CEA test was ordered during a single month (October) of 1979. This month was chosen in advance because a stable hospital census was anticipated without prolonged holidays and without influx of new house staff. Information adequate for a complete data base was available for 103 (93%) Of the CEAs ordered, Sample 2 was chosen at random from a list of all CEA tests performed in 1979 by utilizing a table of random 5-digit numbers (Rand Corporation). Of the 107 CEA tests selected in this way, the medical record was available and adequately informative in 106 (99.1%). Nonavailfibility of the patient's hospital chart was the principal reason for exclusion (eight in sample 1, one in sample 2). Categories were established prior to data collection (carded out by J.K.R. and S.L.V.) for recording specific information upon each CEA determination under study including (1) reason for MD order [follow/detect colon-/other (named) cancer] with an estimate of clarity with which that reason could be determined (stated, apparent, not obvious); (2) department and training level of the ordering physician; (3) the smoking status and age of the patient. For sample 2, in addition, the record was carefully scrutinized for changes in management (either in workup or therapy) that occurred within three months of the time the CEA value was known. When a management change was found, a determination was made as to whether the change was directly related to the CEA test result. Criteria for deciding whether the CEA value had a direct effect on patient management included (1) the physician's written rationale for the management change as contained in the medical record; (2) the temporal sequence of events (was the change made before the CEA value was known?); and (3) the nature of the other data (liver biopsy documenting metastatic disease or normal barium enema and colonoscopy, for example) available to the physician at the time of the management change.
RESULTS
Physician Perception of the Test. Over 50% of 45 medical center physicians questioned (sample t) thought the CEA test to be useful in initial detection of colonic cancer, and many felt it to be useful in detecting six other tumor types as well (Table 1) . With regard to management of patients with colonic carcinoma (ie, in the follow-up period after operation or chemotherapy), 91% of physicians (41/45) thought the CEA determination was of value. In addition 9% or more believed the CEA test to have utility in the diagnosis or management of tumors in the uterus/vagina, lung, breast, and pancreas (Table   I ).
Given a CEA determination in a nonsmoking previously healthy patient, the level (ng/ml) that physicians indicated would cause them to undertake an aggressive workup to rule out cancer is shown in Figure 2 ; note that a stated precondition was that physical examination and routine laboratory examination (chem 18, urine analysis, chest xray) had yielded no evidence for malignancy. While 11% of physicians would ignore any value in this circumstance and 15% had no opinion, 69% said that at a particular level of CEA, most commonly 10-25 ng/ml (or 4-10 times normal), they would initiate such a workup. With regard to the value of CEA in the postoperative period after resection of a colon carcinoma, a majority (53.3%) believed it to be of value only if the preoperative CEA was elevated; 20 physicians (44%) thought it useful regardless of the preoperative CEA level; and 10 (22%) felt that it was of value even in the patient with known metastatic disease. None thought the test to be of no value.
Physician opinion varied regarding the percentage of colonic cancer recurrences that is accompanied by an increase in CEA level. While the most frequent response given was 51-75% of recurrences, over 30% believed it to be lower and almost a quarter of physicians had "no opinion" on this question (Table 2) . A false-positive rate (raised CEA but no cancer at operation or upon adequate follow-up) under 10% and a false-negative rate (normal CEA in the presence of known recurrence) less than 25% was the view of most MD respondents, although more than 22% had "no opinion" about this aspect of the test.
Knowledge of Cost by the Physician. At a time when a single CEA determination cost the patient (or his insurer) just under $60 at our institution, half the physicians polled believed it to cost less than $30. Seven physicians (15.6%) were above actual cost in their estimates, and one had no opinion.
Actual Usage Patterns as Determined by Review of
Medical Record. CEA orders written by senior staff outnumbered those by house staff in both samples despite the inequality in the number of senior staff (290) compared with house staff (650). When settings for ordering a CEA assay were analyzed by service, surgery (both senior staff and house staff) ordered a far greater number of CEA tests (almost 2:1 in both samples), primarily in monitoring patients who were postoperative for colon cancer. On the other hand, physicians on the medical service tended to use CEA more for the reasons of detection of cancer and follow-up of noncolonic cancer than their surgical colleagues.
The most frequent setting in which a CEA test was ordered was the postoperative follow-up period after resection of a colonic cancer (Figure 3 ). In about a quarter of those patients, metastatic disease was known to be present (see below). Nevertheless, other settings (initial detection of colonic/noncoIonic malignancy; follow-up of noncolonic malignancy), when taken together, outweighed in frequency even colon cancer follow-up in both study samples.
With regard to noncolonic cancer, CEA was used by physicians to follow 12 different types of tumor, with breast, lung, and renal carcinoma being most frequent. On the other hand, CEA was ordered for detection of noncolonic cancer in 31 instances (15% of 209 tests) within our two samples, including breast, lung, pancreas, renal, adrenal, osteogenic, hepatic, and gastric cancer. There were five in- stances in which the CEA was ordered as a "general cancer screen" in patients who presented with nonspecific symptoms and in whom diagnosis was not clear.
Patient Benefit
Resulting from CEA Determinations. The impact of the CEA test upon patient management in terms of additional workup performed and/or diagnoses made and therapy administered was carefully evaluated in the randomly selected sample (sample 2) ( Table 3) . No change in management (workup or therapy) occurred in the large majority of patients (87/105).
In 18 additional patients, a management change was made, but it was initiated in response to other information (enlarging tumor mass or positive liverspleen scan, for example) and not in response to the CEA value by the preestablished criteria stated above (see Materials and Methods). In only one patient did a CEA value result in a change in workup, although, unfortunately, without benefit. A 58-year-old female, who had undergone a resection two years previously for colonic cancer, was reoperated because of a rising CEA (7 to 28 ng/ml over three months). No recurrence was found at laparotomy, and the patient has continued to remain symptom-free for six months. The chance of falsely accepting the hypothesis of no patient benefit from CEA in our study ([3 error) is quite small. Thus, if we were to demand that CEA use result in patient benefit in at least 2% of instances in which it is used, there is less than one chance in ten that our sample would not have detected it, ie, 13 < 0.11, power > 0.89. For a 3% benefit, the corresponding values would be 13 = 0.04, power = 0.96.
It is of interest that the result of the CEA assay was not noted in the chart by an MD in 70 of the 105 instances in which it was ordered (Table 3) . Nevertheless, a change in management occurred with equal frequency (12/70, 6/35, both 16%) whether the CEA was noted by the physician or not.
Characteristics of Study Population Samples.
The clarity with which one could deduce from the medical record the precise reason for ordering a CEA determination was separately tabulated. While in only a few percent of cases (2-5%) was the reason explicitly stated, it was readily apparent from the clinical setting in 89-90% of the instances. In cases where a reason for the order was not obvious (5-8% of each sample), a careful review of the record usually permitted assignment to the broad categories of detection versus follow-up of cancer and the type of malignancy involved. Further, within each sample, one fourth to one third of patients were known to have metastatic disease at the time the CEA test was ordered.
DISCUSSION
Several contentions concerning current usage of the CEA assay would seem to be confirmed by this study, namely that this test is often ordered inappropriately (initial detection of cancer); in settings where payoff is very low (follow-up of noncolonic malignancy); and in circumstances where the falsepositive and -negative rates as well as cost are inaccurately known by the physician. Most large studies have documented the nonutility of the CEA measurement for the initial detection of cancer, including that of the colon. Wanebo et al found CEA values to be elevated (>5 ng/ml) in only 4% of Duke's A and 26% of Duke's B disease, lesions that ideally should be detected early because they have the highest potential cure rate (7) . Further, a large collaborative study of patients suspected of having colon pathology reported that about 30% of those with newly diagnosed colonic cancer had a normal serum CEA. This study also demonstrated a high false-positive rate for CEA, occurring in 35% of a group of patients initially suspected of, but later proven not to have, colonic carcinoma (8) . Other studies have documented a markedly increased prevalence of elevated CEA in several nonmalignant conditions (9) (10) (11) (12) (13) (14) , including alcoholic liver disease (88%), cryptogenic cirrhosis (78%), benign biliary obstruction with inflammation (52%) (15) , and ulcerative colitis (16) . Even the manufacturer's package insert for the assay does not suggest a role for the test in initial detection of cancer.
In the current study, the percentage of physicians that believed CEA measurements to be of value in the initial detection of colon carcinoma was 51%; of pancreatic carcinoma, 13%; and of lung cancer, 9%. In actual practice, more than 22% of CEAs ordered in our study were for initial detection of cancer, with tumor site split equally between colonic and other sites of origin. As already noted, neither the literature nor the manufacturer's instructions would appear to support this practice.
Past studies vary in their assessment of the usefulness of serial CEA determinations in following patients whose colonic cancer has been resected. Thus, while Minton found that 4 of 19 patients with steadily rising serum CEAs who underwent aggressive reoperation for resection remained disease-free at eight years (17), Shani et al (18) as well as others (19, 20) have found that serial CEA measurements in such patients had little value beyond that provided by the standard clinical assessment, ie, periodic history, physical examination, proctoscopy, and/or barium enema.
In the present study, a large proportion of physicians believed CEA to be useful in the follow-up of cancer of the colon (41/45, 91%) and some would use it in following cancer of the pancreas (15/52, 33%) and breast (12/52, 29%). Their actual practice reflected their views, as 44% (47/106) of tests were ordered on patients postoperative for colon cancer, and 23% (26/106) on patients with a history of other malignancies (sample 2). An array of 12 types of noncolonic tumors were being followed with CEA, including adrenal, osteogenic, renal and brain primaries, lesions for which there have been no large systematic controlled studies evaluating the efficacy of CEA for long-term monitoring. An exception may be breast cancer, where 53-71% of patients, depending upon the series, with known metastatic disease, particularly with spread to the liver, are reported to have elevated CEA (21, 22) . There is little data to indicate the utility of CEA in estimating the remaining tumor burden or clinical status in patients undergoing radiation or chemotherapy for noncolonic malignancy.
For patients postoperative for colonic cancer, physician perception of the true positive rate for the CEA test (50-75%) matched findings in the literature for all patients with recurrence including those with inoperable metastases (19, 23) . However, a far lower (25-30%) prevalence of CEA positivity is suggested in large series for patients with potentially curable locally recurrent disease (24, 25) .
The rate of false positives reported in the literature varies with the level of CEA chosen as abnormal, the length of follow-up, and peculiarities of the patient population studied. Thus, Mackay reported that of 220 such patients followed, 17 (7.7%) demonstrated an elevated CEA without evidence of recurrence at a minimum of 12 months (23). Mach, in following 66 patients previously resected for cure, noted a CEA greater than 5 ng/ml in 12 (18%) despite the absence of recurrence at 1 1/2-5 years (26) . In all cases of apparent false positives, however, the CEA level was <16 ng/ml. Likewise, the incidence of false-negative values (known cancer recurrence, normal CEA) is as low as 29-32% when one considers all patients with recurrence including those with distant metasteses, but rises to 66-95% if one studies patients with only local disease who might benefit from further resection (23, 27 ). In the current study, over half the physician s (23/45, 51.1%) felt that the false-positive rate was under 10%.
Meeker, in a 1976 retrospective chart-review study of 437 CEA tests ordered over a 6-month period, reported that usage of CEA by the medical service was primarily in a nonneoplastic setting, 95% of tests being single determinations for diagnostic purposes and none leading to a change in management (28) . For the one postoperative patient in that series who underwent resection for local recurrence of colonic adenocarcinoma, the cost of CEA assays per patient whose prognosis may have been changed was at least $10,000 (COSt of a single test was $30, or half that in the current study) (29) . Unfortunately, neither patient outcome data nor the results of sensitive standard follow-up m0dalities (air-contrast barium enema and proctoscopy/colonoscopy) were reported in this series. Hence, an assessment of true patient benefit from CEA was not possible.
No patient benefit from CEA determinations could be documented in a random subset of 106 patients studied in detail in the current study. If our sample is reasonably representative of all CEA tests ordered at oUr institution in 1979, it would argue that the money spent (over $70,000 at $60/test) had a cost-to-benefit ratio which was quite 10w. Fur: ther, to the extent that our experience with CEA reflects generally on utilization of small laboratory tests and procedures, undiscerning use by physicians of the clinical laboratory would seem to be prevalent. The discrepancy documented here between proven indications for CEA measurement and current physician use and perception makes it imperative that we continue to inform and educate our colleagues about relatively expensive tests that have only specific and quite limited application. 
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